Skip to content
WeighLab
Menu

Head-to-head · Cost-Efficiency Index

Gala Health vs Navio MD

Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.

Grade C · #63

Gala Health

Women who have already committed to a full year and want one all-doses-included rate — plus, unusually, an HRT and menopause line running on the same account as the weight program.

Visit Gala Health
VS
Better valueGrade C · #69

Navio MD

Shoppers who want compounded tirzepatide with a brand-name fallback path on the same platform, 48 states.

Visit Navio MD

The verdict

Winner · Navio MDGrade C vs C

Navio MD takes it, leading the Cost-Efficiency Index 73 to 71. NavioMD is a 48-state telehealth platform selling compounded tirzepatide from $189/mo plus brand-name Ozempic, Zepbound, and Mounjaro at near-retail 'as low as' prices. Gala Health still earns a CWomen who have already committed to a full year and want one all-doses-included rate — plus, unusually, an HRT and menopause line running on the same account as the weight program.

Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Navio MD.

Factor by factor

Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.

Normalized Cost/Month

74
61

Price Transparency

62
78

Nationwide Access

76
78

Formulation Options

82
79

Clinical Oversight

80
87

Contract Flexibility

50
55

Pricing, coverage & formulary

The disclosed facts behind the scores. Lower price wins its row (teal).

SpecGala HealthNavio MD
Cost-Efficiency Index71/10073/100
Semaglutide / moNo compounded option — brand Ozempic only, $1,299/mo$345/mo (brand Ozempic)
Tirzepatide / mo$179/mo (yearly subscription; $199/mo on a 3-month plan)$189/mo (starting dose, compounded)
Semaglutide / yr (modeled)$4,140
Tirzepatide / yr (modeled)$2,148$2,268
Coverage50 states claimed, no list published48 states
Oral / sublingualNoNo
Brand-name accessYesYes
Rank here#63#69

Gala Health

71/100

Where the value is

  • $179/mo on a yearly subscription, with every dose included, so the price does not climb as you titrate — dose escalation is where most flat-looking programs quietly get expensive
  • The price list is PUBLIC and un-gated: the weight tier, the $149 microdosing tier and the brand tier are all printed before any quiz, intake or email capture
  • Both compounded molecules — semaglutide and tirzepatide — prescribable on one account

The tradeoffs

  • No month-to-month price exists anywhere on the site. "FROM $179/month" sits directly above "All doses included. Yearly subscription.", and the cheapest alternative the FAQ names is "$199 per month (with a 3-month plan)" — three months is the shortest published commitment there is
  • $179/mo is $2,148 committed for the year, and that total is printed nowhere: the site quotes a monthly figure for a purchase it only sells annually, which is the single hardest cost in this ranking to compare against a rate you can cancel next month
Visit Gala Health

Full Gala Health review →

Navio MD

73/100

Where the value is

  • LegitScript certified with board-certified providers claimed
  • Both compounded and brand-name options on one platform
  • 48-state coverage with the two exclusions (AL, MS) explicitly disclosed rather than hidden

The tradeoffs

  • No compounded semaglutide offered — only brand-name Ozempic for that molecule, at a much higher price than compounded competitors
  • All prices are 'as low as' floors; the exact dose tied to each starting price is not published
Visit Navio MD

Full Navio MD review →

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.

Keep comparing

← All head-to-head comparisons